Marc Dunoyer: Thank you, Mene, and please turn to Slide 26. Year-to-date, rare disease total revenue grew 10% on a pro forma basis, contributing $5.2 billion. Over this period, we saw continued durability of our C5 franchise with increasing conversion to Ultomiris across PNH, typical aHUS, myasthenia gravis as well as strong demand for Strensiq in HPP. Performance in the period also benefited from geographic expansion across already this portfolio. In the third quarter, rare disease contributed over $1.7 billion in total revenues, representing 11% pro forma growth at constant exchange rate. The C5 franchise grew 8% with Soliris declining 6% in the quarter, reflecting the successful conversion to Ultomiris in PNH, a typical aHUS and myasthenia gravis.
Conversion was partially offset by growth in NMO were Soliris remains the market share leader. Ultomiris delivered growth of 47% in the third quarter, driven by expansion into new markets as well as the acceleration of the as myasthenia gravis is launched in the United States. Beyond the C5 franchise, Strensiq delivered 20% growth in the quarter driven by strong demand in the United States. Koselugo go now available in 20 markets also contributed significant growth in the quarter and was granted priority review in China. In the third quarter, performance across the U.S., Europe and established rest of the world were stable, while emerging market growth of 61% reflect viability of order timing in certain tender markets when comparing to prior year periods.
On Slide 27, I’d like to take a few moments to review highlight from our rare disease event, the full recording of which is available on our Web site. We remain leaders in rare disease with a pioneering C5 franchise, which will deliver growth over the near to midterm and our novel complement and beyond complement medicine, which will help support AstraZeneca longer growth ambitions. We announced Ultomiris will be available in 85 countries by the end of next year, any indicated plans to pursue label expansion for cardiac surgery associated AKI haematopoietic stem cell transfer TMA boasts potential blockbusters opportunities. Beyond our C5 franchise, we continue to progress of our oral factor D complement medicine and reported Phase III data for danicopan in PNH patients with clinically significant extravascular hemolysis, which represents 10% to 15% of the overall PNH population, not presently managed with Ultomiris.
Our next generation oral factor D, vemircopan as dosed Phase II trials for myasthenia gravis and renal indications and our Phase II PNH monotherapy trial is nearing completion. Beyond complement, we highlighted plans to initiate a Phase III program for Alexion-1850, our next generation medicine for HPP following Phase I results. We expect Alexion-1850 can more than double the addressable population of Strensiq, given an expanded label and more favorable dosing portfolio. We also continue to advance our exciting portfolio of novel for the treatment of amyloidosis, which have the potential to bind in clear febrile deposition in tissue and potentially reverse the cause of the disease. Phase III trials for CAEL-101 in light chain Amyloidosis are progressing, and we see significant potential for NI006 for the treatment of TTR cardiomyopathy.
Next, we continue to build bridges with AstraZeneca to maximize our commercial capabilities and operation network. And as you heard, Aradhana speak to you earlier, we are delivering on our commitment at the time of acquisition, and we plan to expand a rare disease portfolio into 100 countries by 2030. As part of our bridges, we highlighted the opportunity to apply AstraZeneca existing genomic medicine technologies for rare disease, and made additional progress in this effort with a proposed acquisition of LogicBio, a genomic medicine company based outside of Boston, Massachusetts. Now turning to Slide 28. This acquisition enhances our existing genomic medicine capabilities, bringing in-house a team of talented researchers, as well as three novel technologies that will help accelerate ongoing effort, including a proprietary AAV manufacturing platform aimed to improve product yields and quality.
